Estradiol induces bone osteolysis in triple–negative breast cancer via its membrane–associated receptor ERα36
Triple–negative breast cancer (TNBC) is thought to be an estradiol–independent, hormone
therapy–resistant cancer because of lack of estrogen receptor alpha 66 (ERα66). We …
therapy–resistant cancer because of lack of estrogen receptor alpha 66 (ERα66). We …
Estradiol induces bone osteolysis in triple–negative breast cancer via its membrane–associated receptor ERα36
DJ Cohen, CD Dennis, J Deng, BD Boyan… - JBMR Plus, 2024 - academic.oup.com
Triple–negative breast cancer (TNBC) is thought to be an estradiol–independent, hormone
therapy–resistant cancer because of lack of estrogen receptor alpha 66 (ERα66). We …
therapy–resistant cancer because of lack of estrogen receptor alpha 66 (ERα66). We …
Estradiol induces bone osteolysis in triple-negative breast cancer via its membrane-associated receptor ERα36
DJ Cohen, CD Dennis, J Deng, BD Boyan… - JBMR …, 2024 - pubmed.ncbi.nlm.nih.gov
Triple-negative breast cancer (TNBC) is thought to be an estradiol-independent, hormone
therapy-resistant cancer because of lack of estrogen receptor alpha 66 (ERα66). We …
therapy-resistant cancer because of lack of estrogen receptor alpha 66 (ERα66). We …
Estradiol induces bone osteolysis in triple-negative breast cancer via its membrane-associated receptor ERα36.
DJ Cohen, CD Dennis, J Deng, BD Boyan, Z Schwartz - JBMR Plus, 2024 - europepmc.org
Triple-negative breast cancer (TNBC) is thought to be an estradiol-independent, hormone
therapy-resistant cancer because of lack of estrogen receptor alpha 66 (ERα66). We …
therapy-resistant cancer because of lack of estrogen receptor alpha 66 (ERα66). We …
[HTML][HTML] Estradiol induces bone osteolysis in triple–negative breast cancer via its membrane–associated receptor ERα36
DJ Cohen, CD Dennis, J Deng, BD Boyan… - JBMR Plus, 2024 - ncbi.nlm.nih.gov
Triple–negative breast cancer (TNBC) is thought to be an estradiol–independent, hormone
therapy–resistant cancer because of lack of estrogen receptor alpha 66 (ERα66). We …
therapy–resistant cancer because of lack of estrogen receptor alpha 66 (ERα66). We …
Estradiol induces bone osteolysis in triple–negative breast cancer via its membrane–associated receptor ERα36
DJ Cohen, CD Dennis, J Deng, BD Boyan, Z Schwartz - 2024 - europepmc.org
Triple–negative breast cancer (TNBC) is thought to be an estradiol–independent, hormone
therapy–resistant cancer because of lack of estrogen receptor alpha 66 (ERα66). We …
therapy–resistant cancer because of lack of estrogen receptor alpha 66 (ERα66). We …